Compare WOW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOW | DMAC |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.5M | 428.6M |
| IPO Year | 2017 | N/A |
| Metric | WOW | DMAC |
|---|---|---|
| Price | $5.20 | $7.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.20 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 556.6K | 442.9K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $590,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $3.19 |
| 52 Week High | $5.33 | $10.42 |
| Indicator | WOW | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 44.35 |
| Support Level | $5.16 | $8.16 |
| Resistance Level | $5.23 | $8.45 |
| Average True Range (ATR) | 0.02 | 0.50 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 57.14 | 6.03 |
WideOpenWest Inc is a cable operator and broadband service, provider. The company serves residential, business and wholesale customers in Illinois, Michigan, Indiana, Ohio, Kansas, Tennessee, Maryland, and South Carolina. Its service portfolio consists of high-speed internet, data, voice, cloud, and cable television services. The company operates in one business segment that is Broadband Services. The majority of the revenue is generated from the subscription service revenue received.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.